stockrowMacroGenics, Inc.
MGNXMacroGenics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.5 million, roughly unchanged from fiscal 2024.
- Revenue
- +47.6%
- EPS
- +154.4%
- Free cash flow
- +12.9%
Quarter to June 2026, against a year earlier
Follow MGNX
Alert me
MacroGenics, Inc. (MGNX) EV/Sales
As of 6 November 2026, MacroGenics, Inc. (MGNX) trades at a EV/Sales of −0.1×. Over the past ten years it has ranged from −0.8× (March 2025) to 52.4× (November 2017); the current reading is higher than 9% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.5× | — |
| FY2024 | 0.1× | (99.21%) |
| FY2023 | 6.9× | 333.66% |
| FY2022 | 1.6× | (82.93%) |
| FY2021 | 9.4× | 5.25% |
| FY2020 | 8.9× | 81.92% |
| FY2019 | 4.9× | 0.21% |
| FY2018 | 4.9× | 91.29% |
| FY2017 | 2.5× | (43.79%) |
| FY2016 | 4.5× | (29.85%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.8× | 234.78% |
| Mar 2026 | 0.2× | — |
| Dec 2025 | −0.5× | — |
| Sep 2025 | −0.3× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGNX MacroGenics, Inc. | −0.1× |
| NGEN NervGen Pharma Corp. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | 0.1× |
| INO Inovio Pharmaceuticals, Inc. compare | 206× |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)